Cardiol Res

Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access

Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc

Journal website http://www.cardiologyres.org

Original Article

Volume 10, Number 2, April 2019, pages 89-97

Long-Term Survival After Stroke According to Reperfusion Therapy, Cardiovascular Therapy and Gender

Figure 3. Survival probability for medical therapy including intravenous thrombolysis (group I) according to sex.

Figure 4. Survival curve for mechanical thrombectomy with or without intravenous thrombolysis (group II) according to sex.

**Table 1.** Baseline Characteristics by Sex
Variable	Thrombolytic therapy	Thrombolytic therapy and/or thrombectomy	Medical therapy alone
Cases number	521 (49.2)	538 (50.8)	0.335	1,059	165 (43.9)	211 (56.1)	0.011	376	6,530 (50.0)	6,521 (50.0)		13,051
Age (average) ± SD	77.87 ± 8.4	73.12 ± 9.9	< 0.001	75.45 ± 9.5	70.48 ± 11.2	68.64 ± 11.	0.11	69.45 ± 11.1	80.3 ± 10.1	74.4 ± 11.1	< 0.001	77.4 ± 11.0
Age groups			< 0.001				0.019				< 0.001
< 15 years old	0	0	-	0	0	1		1	0	1		1
15 - 59	20 (3.8)	54 (10.0)	< 0.001	75	27 (16.4)	34 (16.1)		61	302 (4.6)	661 (10.1)		963
60 - 69	58 (11.1)	118 (21.9)	< 0.001	176	36 (21.8)	63 (29.9)		99	532 (8.1)	1,335 (20.5)		1,867
70 - 79	176 (33.8)	214 (39.8)	< 0.001	390	64 (38.8)	90 (42.7)		154	1,655 (25.3)	2,080 (31.9)		3735
80 - 89	244 (46.8)	144 (26.8)	< 0.001	388	38 (23.0)	23 (10.9)		61	3,052 (46.7)	2,094 (32.1)		5,146
> 90 years old	23 (4.4)	8 (1.5)	< 0.001	31	-	-		-	989 (15.1)	350 (5.4)		1,339
Primary outcome (mortality at 5 years)	274 (52.6)	249 (46.3)	0.023	523 (49.4)	57 (34.5)	92 (43.6)	0.047	149 (39.6)	4,005 (61.3)	3,447 (52.9)	< 0.001	7,452 (57.1)
Cumulated proportion survival at 5 years	0.38	0.47	0.023	0.42	0.56	0.49	0.116	0.52	0.29	0.37	< 0.001	0.33
Hemorrhagic stroke post-	6	4	0.075	10	1	3	0.587	4	72	150	0.075	222 (97.7)

Table 1. Baseline Characteristics by Sex

Variable

Thrombolytic therapy

Thrombolytic therapy and/or thrombectomy

Medical therapy alone

Women

Men

All

Women

Men

All

Women

Men

All

Cases number

521 (49.2)

538 (50.8)

0.335

1,059

165 (43.9)

211 (56.1)

0.011

376

6,530 (50.0)

6,521 (50.0)

13,051

Age (average) ± SD

77.87 ± 8.4

73.12 ± 9.9

< 0.001

75.45 ± 9.5

70.48 ± 11.2

68.64 ± 11.

0.11

69.45 ± 11.1

80.3 ± 10.1

74.4 ± 11.1

< 0.001

77.4 ± 11.0

Age groups

< 0.001

0.019

< 0.001

< 15 years old

15 - 59

20 (3.8)

54 (10.0)

< 0.001

27 (16.4)

34 (16.1)

302 (4.6)

661 (10.1)

963

60 - 69

58 (11.1)

118 (21.9)

< 0.001

176

36 (21.8)

63 (29.9)

532 (8.1)

1,335 (20.5)

1,867

70 - 79

176 (33.8)

214 (39.8)

< 0.001

390

64 (38.8)

90 (42.7)

154

1,655 (25.3)

2,080 (31.9)

3735

80 - 89

244 (46.8)

144 (26.8)

< 0.001

388

38 (23.0)

23 (10.9)

3,052 (46.7)

2,094 (32.1)

5,146

> 90 years old

23 (4.4)

8 (1.5)

< 0.001

989 (15.1)

350 (5.4)

1,339

Primary outcome (mortality at 5 years)

274 (52.6)

249 (46.3)

0.023

523 (49.4)

57 (34.5)

92 (43.6)

0.047

149 (39.6)

4,005 (61.3)

3,447 (52.9)

< 0.001

7,452 (57.1)

Cumulated proportion survival at 5 years

0.38

0.47

0.023

0.42

0.56

0.49

0.116

0.52

0.29

0.37

< 0.001

0.33

Hemorrhagic stroke post-

0.075

0.587

150

0.075

222 (97.7)

**Table 2.** Treatments by Sex
Variables	Thrombolytic therapy	Thrombolytic therapy and/or thrombectomy	Medical therapy alone
ACEI: angiotensin converting enzyme inhibitor; AII-RA: angiotensin II receptor antagonists.
Anticoagulants (%)	34 (6.5)	35 (6.5)	0.544	69 (6.5)	33 (20.0)	28 (13.3)	0.053	61 (16.2)	949 (14.5)	782 (12.0)	< 0.001	1731 (13.3)
Antiaggregants (%)	246 (47.2)	297 (55.2)	0.006	543 (51.3)	61 (37.0)	104 (49.3)	0.011	165 (43.9)	3,216 (49.2)	3,722 (57.1)	< 0.001	6,938 (53.2)
Statins (%)	221 (42.4)	282 (52.4)	0.001	503 (47.5)	75 (45.5)	123 (58.3)	0.009	198 (52.7)	2,777 (42.5)	3,255 (49.9)	< 0.001	6,032 (46.2)
Antidiabetics (%)	98 (18.8)	141 (26.2)	0.002	239 (22.6)	33 (20.0)	52 (24.6)	0.173	85 (22.6)	1,698 (26.0)	2,138 (32.8)	< 0.001	3,836 (29.4)
Diuretics (%)	203 (39.0)	144 (26.8)	< 0.001	347 (32.8)	58 (35.2)	50 (23.7)	0.01	108 (28.7)	2,953 (45.2)	2,038 (31.3)	< 0.001	4,991 (38.2)
ACEIs (%)	176 (33.8)	172 (32.0)	0.287	348 (32.9)	57 (34.5)	74 (35.1)	0.502	131 (34.8)	2,425 (37.1)	2,652 (40.7)	< 0.001	5,077 (38.9)
AII-RA	178 (34.2)	153 (28.4)	0.026	331 (31.3)	47 (28.5)	61 (28.9)	0.511	108 (28.7)	1,975 (30.2)	1,706 (26.2)	< 0.001	3,681 (28.2)
Beta-blocker	176 (33.8)	176 (32.7)	0.381	352 (33.2)	49 (29.7)	75 (35.3)	0.139	124 (33.0)	1,798 (27.5)	1,616 (24.8)	< 0.001	3,414 (26.2)

Table 2. Treatments by Sex

Variables

Thrombolytic therapy

Thrombolytic therapy and/or thrombectomy

Medical therapy alone

Women

Men

All

Women

Men

All

Women

Men

All

ACEI: angiotensin converting enzyme inhibitor; AII-RA: angiotensin II receptor antagonists.

Anticoagulants (%)

34 (6.5)

35 (6.5)

0.544

69 (6.5)

33 (20.0)

28 (13.3)

0.053

61 (16.2)

949 (14.5)

782 (12.0)

< 0.001

1731 (13.3)

Antiaggregants (%)

246 (47.2)

297 (55.2)

0.006

543 (51.3)

61 (37.0)

104 (49.3)

0.011

165 (43.9)

3,216 (49.2)

3,722 (57.1)

< 0.001

6,938 (53.2)

Statins (%)

221 (42.4)

282 (52.4)

0.001

503 (47.5)

75 (45.5)

123 (58.3)

0.009

198 (52.7)

2,777 (42.5)

3,255 (49.9)

< 0.001

6,032 (46.2)

Antidiabetics (%)

98 (18.8)

141 (26.2)

0.002

239 (22.6)

33 (20.0)

52 (24.6)

0.173

85 (22.6)

1,698 (26.0)

2,138 (32.8)

< 0.001

3,836 (29.4)

Diuretics (%)

203 (39.0)

144 (26.8)

< 0.001

347 (32.8)

58 (35.2)

50 (23.7)

0.01

108 (28.7)

2,953 (45.2)

2,038 (31.3)

< 0.001

4,991 (38.2)

ACEIs (%)

176 (33.8)

172 (32.0)

0.287

348 (32.9)

57 (34.5)

74 (35.1)

0.502

131 (34.8)

2,425 (37.1)

2,652 (40.7)

< 0.001

5,077 (38.9)

AII-RA

178 (34.2)

153 (28.4)

0.026

331 (31.3)

47 (28.5)

61 (28.9)

0.511

108 (28.7)

1,975 (30.2)

1,706 (26.2)

< 0.001

3,681 (28.2)

Beta-blocker

176 (33.8)

176 (32.7)

0.381

352 (33.2)

49 (29.7)

75 (35.3)

0.139

124 (33.0)

1,798 (27.5)

1,616 (24.8)

< 0.001

3,414 (26.2)